Blog

From Inflammation to Hepatitis B

Native CRP Protein and HBsAG Antigen

This is how ‘Native CRP Protein’ and ‘HBsAg Ad/Ay Antigens’ are powering diagnostics

Introduction

In the diagnostic landscape, precision starts with high-quality reagents. Two critical components, C-reactive protein (CRP) for inflammation assays, and HBsAg Ad/Ay antigens for hepatitis B detection are key to developing sensitive, reliable tests capable of delivering accurate results across diverse real-world environments.

In this blog, we will explore:

  • Why native CRP and HBsAg Ad/Ay antigens matter?
  • Their role in current diagnostic markets
  • How they support assay reliability?
  • Why deNOVO Biolabs is a trusted partner?

1. Why is the importance of Native CRP Protein?

CRP is an acute-phase protein produced by the liver in response to inflammation—and it’s a widely adopted biomarker for everything from infection to cardiovascular risk.

  • High-sensitivity CRP (hs-CRP) assays are now an industry standard, especially for evaluating cardiovascular disease risk. In 2024, hs-CRP held nearly 42–43% of the total CRP testing market share globally (Grand View Research, Market.us).
  • The broader global CRP testing market is projected to surge from $2.28 billion in 2023 to $4.17 billion by 2034, growing at a CAGR of approximately 5.6% (Research and Markets).

High-quality native CRP protein ensures consistent calibration, enabling:

  • Accurate quantification across immunoassay types (ELISA, immunoturbidimetry, CLIA)
  • Stability in point-of-care and central lab workflows
  • Reliable detection even at low levels for early disease insight

2. What are HBsAg Ad/Ay Antigens?

Hepatitis B surface antigen (HBsAg) remains the primary marker for HBV detection. It’s particularly important in the transfusion window period—when early detection of acute or chronic HBV infection is crucial. Globally, an estimated 254 million people live with chronic HBV infection, and nearly 820,000 deaths occurred in 2022 due to HBV-related complications (Wikipedia).

Using HBsAg antigens representing both Ad and Ay subtypes ensures:

  • Broader assay coverage across diverse patient populations
  • Improved sensitivity without compromising specificity
  • More reliable detection in field conditions where subtype prevalence can vary

3. Market & Impact

Diagnostics developers are navigating complex environments, from urban hospitals to remote clinics. Reagents that consistently perform across settings can dramatically reduce validation cycles and regulatory risks.

For CRP:

For HBsAg:

  • With HBV remaining a global health challenge, accurate and early detection through validated antigens is essential for screening and public health programs (Wikipedia).

4. How deNOVO Biolabs adds value?

Benefits of using deNOVO's CRP protein and HBsAg Ad/Ay antigen

5. What does it means for diagnostic developers?

By choosing validated reagents like our native CRP and HBsAg pairs, you gain:

  • Smoother assay development and validation
  • Reduced variability across test batches
  • Faster movement from concept to regulatory submission

Ready to strengthen your inflammation and hepatitis B diagnostic workflows?


Contact us for consultation and samples—let’s build diagnostics you can truly rely on.

Leave a Reply

Close Navigation